The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine
Review articleOpen access
2008/11/01 Full-length article DOI: 10.1016/j.ejca.2008.08.010
Journal: European Journal of Cancer
AbstractAimTo describe the healthcare resource consumption of metastatic colorectal cancer (MCRC) patients in the Italian healthcare setting.MethodsA retrospective chart analysis estimating direct medical costs of first-line infusional 5-Fluorouracil (5-FU) or oral Capecitabine (CAP), associated or not with other chemotherapies, from the Italian Healthcare Service (IHCS) and Hospital (H) perspectives.Results202 subjects were analysed. CAP patients (N = 66) were older, with a more compromised clinical status and received less chemotherapy agents in association than 5-FU patients (N = 136). From the IHCS perspective, mean total costs per patient were €12,029 and €5,781 in the 5-FU and CAP arms respectively; €7,338 and €4,688 from the H perspective. The infusional administration route of 5-FU was a cost driver from both perspectives. Sensitivity analyses found the results to be robust to variations in base case parameters.ConclusionsManagement of MCRC by oral chemotherapies may be an economically advantageous option to both IHCS and hospitals.
Request full text